Kurt A. Gustafson
2013 - Halozyme Therapeutics
In 2013, Kurt A. Gustafson earned a total compensation of $691K as Former Vice President and Chief Financial Officer at Halozyme Therapeutics, a 63% decrease compared to previous year.
Compensation breakdown
| Option Awards | $247,733 |
|---|---|
| Salary | $193,290 |
| Stock Awards | $243,660 |
| Other | $6,271 |
| Total | $690,954 |
Gustafson received $247.7K in option awards, accounting for 36% of the total pay in 2013.
Gustafson also received $193.3K in salary, $243.7K in stock awards and $6.3K in other compensation.
Rankings
In 2013, Kurt A. Gustafson's compensation ranked 8,187th out of 12,286 executives tracked by ExecPay. In other words, Gustafson earned more than 33.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 8,187 out of 12,286 | 33rd |
Division Manufacturing | 2,963 out of 4,612 | 36th |
Major group Chemicals And Allied Products | 926 out of 1,466 | 37th |
Industry group Drugs | 703 out of 1,160 | 39th |
Industry Biological Products, Except Diagnostic Substances | 118 out of 200 | 41st |
Source: SEC filing on April 7, 2014.
Gustafson's colleagues
We found five more compensation records of executives who worked with Kurt A. Gustafson at Halozyme Therapeutics in 2013.
2013
David Ramsay
Halozyme Therapeutics
Chief Financial Officer
2013
Gregory Frost
Halozyme Therapeutics
Chief Executive Officer
2013
James Shaffer
Halozyme Therapeutics
Former Vice President and Chief Commercial Officer
2013
Jean Liu
Halozyme Therapeutics
General Counsel
2013
H Shepard
Halozyme Therapeutics
Chief Scientific Officer
News
OmniAb CEO Matthew Foehr's 2023 pay falls 60% to $2.6M
April 26, 2024
OmniAb CEO Matthew Foehr's 2022 pay jumps 26% to $6.7M
May 1, 2023
Spectrum Pharmaceuticals CEO Joseph Turgeon's 2021 pay jumps 110% to $7.8M
April 27, 2022
Spectrum Pharmaceuticals CEO Joseph Turgeon's 2019 pay jumps 21% to $5.7M
April 22, 2020
Spectrum Pharmaceuticals COO Thomas Riga's 2018 pay jumps 388% to $5.3M
April 23, 2019